Failure to detect Xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome by Hong, Ping et al.
RESEARCH Open Access
Failure to detect Xenotropic murine leukaemia
virus-related virus in Chinese patients with
chronic fatigue syndrome
Ping Hong
1,2, Jinming Li
1,2*, Yongzhe Li
3*
Abstract
Background: Recent controversy has surrounded the question of whether xenotropic murine leukaemia virus-
related virus (XMRV) contributes to the pathogenesis of chronic fatigue syndrome (CFS). To investigate the
question in a Chinese population, 65 CFS patients and 85 blood donor controls were enrolled and multiplex real-
time PCR or reverse transcriptase PCR (RT-PCR) was developed to analyze the XMRV infection status of the study
participants. The assay was standardized by constructing plasmid DNAs and armored RNAs as XMRV standards and
competitive internal controls (CICs), respectively.
Results: The sensitivities of the multiplex real-time PCR and RT-PCR assays were 20 copies/reaction and 10 IU/ml,
respectively, with 100% specificity. The within-run precision coefficient of variation (CV) ranged from 1.76% to
2.80% and 1.70% to 2.59%, while the between-run CV ranged from 1.07% to 2.56% and 1.06% to 2.74%. XMRV was
not detected in the 65 CFS patients and 65 normal individuals out of 85 controls.
Conclusions: This study failed to show XMRV in peripheral blood mononuclear cells (PBMCs) and plasma of
Chinese patients with CFS. The absence of XMRV nucleic acids does not support an association between XMRV
infection and the development of CFS in Chinese.
Background
Chronic fatigue syndrome (CFS) is a multisystem disease
which is characterized by severe and debilitating fatigue,
abnormal sleep behaviour, impaired memory and con-
centration, and musculoskeletal pain [1]. The constella-
tion of symptoms is non-specific and can be caused by a
variety of diseases. Studies have identified various fea-
tures relevant to the pathogenesis of CFS, such as viral
infection, abnormal immune function, exposure to tox-
ins, chemicals and pesticides, stress, hypotension, abnor-
mal lymphocyte levels, and neuroendocrine dysfunction.
However, the precise underlying mechanisms of the dis-
ease and the means by which they interact in patients
with CFS remain to be clarified [2].
Recent works have emphasized the frequent associa-
tion of CFS with gammaretrovirus (XMRV) infection,
although the role of XMRV as a causative agent of CFS
remains controversial. In a recent US study, Lombardi
et al [3] found that about 67% (68/101) of patients with
CFS carried detectable levels of XMRV DNA in their
peripheral blood mononuclear cells (PBMCs). Moreover,
replicating virus was isolated from stimulated PBMCs in
vitro. If confirmed, these findings would have a serious
impact on understanding the pathogenesis of this com-
plex and debilitating disease. However, another 3 recent
reports showed that XMRV was absent in PBMCs from
European CFS patients [4-6]. The results were similar in
a recent report from the US [7], leading to an intense
scientific debate over the relationship between the virus
and CFS [8]. It is not yet clear whether the distribution
o ft h i sv i r u si sp r i m a r i l yd e p e n d e n to ng e o g r a p h i c
restrictions or, more likely, the diagnostic techniques
used, such as PCR and real-time PCR. In terms of meth-
odology, one of the risks associated with testing samples
by PCR is the frequent occurrence of false negatives as
a result of PCR inhibition [9]. The inclusion of an inter-
nal control (IC) serves as a monitor for false negatives
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may be present in clinical samples [10]. In previous stu-
dies of XMRV detection [4-7], non-competitive ICs,
such as GAPDH, were used to monitor for false-nega-
tive reactions. In the non-competitive IC strategy, sepa-
rate primer pairs are used to detect the IC and the
target nucleic acid. Nevertheless, the non-competitive
ICs may introduce different amplification efficiencies
due to their natural inter-individual variation, and may
produce false-negative results. This matter is of consid-
erable importance in the extensive controversy sur-
rounding XMRV detection in CFS patients.
A review of the diverse results from previous studies
reveals several questions about worldwide distribution
and whether the retrovirus is linked to CFS, at all. Until
now, no information has been published regarding
XMRV infection in Chinese CFS sufferers. We developed
sensitive multiplex real-time PCR and reverse transcrip-
tase PCR (RT-PCR) assays, using a competitive internal
control (CIC) strategy to ensure PCR integrity and elimi-
nate false-negative results, to detect XMRV proviral
DNA and viral RNA, respectively, in the PBMCs and
plasma of Chinese CFS patients. The assays were standar-
dized using constructed XMRV DNA or armored RNA
standards, and their performances were evaluated.
Materials and methods
Study subjects and samples
Sixty-five CFS patients and 85 blood donors, including
65 healthy controls and 20 controls with hepatitis B,
hepatitis C, human immunodeficiency virus type 1 infec-
tion, or human T-cell leukaemia virus infection (con-
firmed at the blood bank) were enrolled. Patients and
controls were closely matched for age, sex, and place of
residence. Both groups were aged between 20 and 55
years, and the ratios of women to men were 35:30 (CFS)
and 44:41 (blood donors). Samples were collected from
2007 to 2009. CFS patients were recruited from clinics
in Peking Union Medical College Hospital. All patients
underwent full medical and neurological evaluations and
were tested to exclude alternative explanations for their
symptoms. Additionally, they fulfilled the 1994 interna-
tional research criteria for diagnosis of CFS [1], which
r e q u i r e st h ep r e s e n c eo ff a t i g u ew i t h4o rm o r ea d d i -
tional symptoms and was established to help distinguish
CFS from other illnesses that cause fatigue. Blood
donors were enrolled from the Beijing blood centre. All
subjects provided informed consent prior to their parti-
cipation in the study.
Whole blood was obtained by venipuncture from 85
blood donors and 65 CFS patients. PBMCs and plasma
were isolated immediately by Ficoll-Hypaque-1077
( S i g m a )f r o mw h o l eb l o o da n ds t o r e da t- 8 0 ° Cw i t h i n2
hours of sampling.
DNA and RNA preparation
DNA from 100 μl PBMCs (about 5.0 × 10
2 to 2 × 10
3
cells) or RNA from 140 μl plasma was isolated accord-
ing to the manufacturer’s instructions (QIAamp DNA
Blood Mini Kit, QIAamp Viral RNA Mini kit, QIA-
GEN GmbH, Germany); extracted DNA was eluted
in 100 μl DNAse-free water, while RNA was eluted in
60 μl RNase-free water. Both were immediately stored
at -80°C.
Primers and probes
Primers and probes for the XMRV real-time detection
a s s a yw e r ed e s i g n e dt oa m p l i f yr e g i o n so ft h eX M R V
gag gene (nt 462-523). Primer and probe sequences
were optimized using Primer Express (Applied Biosys-
tems) and were synthesized as previously described [11],
to detect both XMRV proviral DNA and XMRV viral
RNA. In order to calibrate the constructed armored
RNAs to an international (IU) value, primers were
designed to amplify regions of the HCV 5′ UTR. Probes
f o rt h ed e t e c t i o no fX M R Va n dC I Cw e r e5 ′-labelled
with 6-carboxyfluorescein (FAM) or 6-carboxyhexa-
chlorofluorescein (HEX), and all were 3′-labelled with
Black Hole Quencher Dye (BHQ). The sequences and
characteristics of the primers and probes are listed in
Table 1.
Preparation of the XMRV DNA standard and the CIC:
recombinant plasmids pACYC-MS2-2V and pACYC-MS2-IC-
2V
An exogenous chimeric sequence 1584 bp in length
was inserted into pACYC-MS2 [12] (previously con-
structed by our laboratory) with three C-variant pac
sites inserted at the beginning, middle, and end. This
sequence was obtained by overlapping extension PCR
[11,12] amplification of XMRV (nt 33 to 1149, 1117
bp amplified from plasmid VP62 [3], kindly provided
by Lombardi; [Genbank: EF185282]) and HCV (nt 25
to 445, 420 bp amplified from pNCCL-HCV [13], con-
structed by our laboratory; [Genbank: AF139594]).
The primers used in this method are shown in
Table 1.
CIC sequences were identical to the 1584-bp exogen-
ous chimeric sequence, except for the probe-binding
sites which were replaced by internal probe sequences
using overlapping extension PCR [14]. The sequence of
these 22 artificial random nucleotides shared a similar
nucleotide composition as the wild type XMRV probe
(Fig. 1).
The resulting recombinant plasmids pACYC-MS2-2V
a n dp A C Y C - M S 2 - I C - 2 Vw e r ev a l i d a t e db ys e q u e n c i n g .
The concentrations of DNA standard and CIC were
assessed by UV-spectrophotometry and DNA copy
numbers were calculated.
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(armored RNAs)
Both pACYC-MS2-2V and pACYC-MS2-IC-2V were
transformed into E. coli strain BL21 (DE3). The armored
RNAs were expressed, purified, and verified [12,13], and
their stabilities were also verified [12,13].
The purified armored RNAs were calibrated against
the World Health Organization (WHO) Second Interna-
tional Standard for HCV RNA (National Institute for
Biological Standards and Controls [NIBSC], code 96/
798, UK), using an HCV RNA PCR fluorescence quanti-
tative diagnostic kit (Shanghai, Kehua) [13]. The samples
were tested in triplicate and the quantification values
were averaged. The concentration of the CIC was evalu-
ated by the same method.
Multiplex real-time PCR and RT-PCR for XMRV detection
Standard DNA and armored RNA were quantified, diluted
to obtain 10-10
6 copies/μl and IU/ml, respectively, and
used to determine the linearity, sensitivity, specificity, and
reproducibility of the multiplex real-time assays. They also
served as external positive controls (EPCs) in the multiplex
real-time PCR and RT-PCR assays.
To determine the optimal CIC concentration for the
real-time assay, a chequer-board assay was performed in
which XMRV standards (10
5 to 10
2 DNA copies/μlo r
10
5 to 10
2 RNA IU/ml) were spiked with 3 different
concentrations (10
5 to 10
3 copies/μl or IU/ml, respec-
tively) of the CIC, and the template mixture was
assayed. Thereafter, it was coamplified or coextracted
and coamplified with the samples in the same reaction
tube. The final optimized PCR mixture (25 μl) contained
12.5 μl QuantiTect Probe PCR or RT-PCR Master Mix
(QIAGEN, QuantiTect Multiplex PCR or RT-PCR kit),
0.4 μM XMRV-specific primers, 0.4 μMX M R V - s p e c i f i c
probes, and 0.2 μM IC-specific probe, 8.3 μl sample (2.0
μlo fX M R VD N A ,1 . 0μl CIC DNA(1000 copies/μl
added during the amplification step), and 5.3 μl DEPC-
treated water ) or 0.25 μl QuantiTect RT Mix, 10 μl
RNA (1000 IU/ml armored RNA CIC added to each
sample prior to extraction). PCR was performed with an
ABI 7500 sequence detection system as follows: an
initial denaturation step at 95°C for 15 min, 45 cycles at
94°C for 15 s and 60°C for 1 min. In addition, the RT-
PCR included an initial reverse transcription step of 50°
C for 30 min.
The linearity and sensitivity of the XMRV assay were
determined by using a dilution series of the DNA or
armored RNA standard (10 copies to 10
6 copies/μlo r
IU/ml, respectively) in PBMCs DNA or plasma from a
healthy donor. To mimic the conditions of the multiplex
real-time PCR or RT-PCR procedures, we also included
a steady concentration of CIC (1000 copies/μlo rI U / m l ,
respectively). Experiments were performed in triplicate
at each concentration.
Forty-five controls, which included 20 subjects with
hepatitis B, hepatitis C, human immunodeficiency virus
type 1 infection, or human T-cell leukaemia virus infec-
tion and 25 out of 65 healthy controls, were used to
determine the specificity of the real-time assay.
The within-run precision of the quantitative real-time
assay was assessed by evaluating 10 replicates of 3 dilu-
tions of the DNA plasmid or armored RNA standard
(10
5,1 0
4,a n d1 0
2 copies/μl or IU/ml, respectively),
while the between-run precision was assessed by testing
the same samples 10 times in 10 separate experiments.
The coefficients of variance (CV) of the threshold cycles
(Ct) were calculated.
Samples from 65 CFS cases and 65 healthy controls
were tested using the standard curve method by multiplex
Table 1 Primer and probe sequences
Primer or probe Sequence (5’-3’)
Gag-1S 5’-TTGGCCGGCCACATGAGGATCACCCATGTCGTGTTCCCAATAAAGCCTTTTGCTGTTTG-3’
Gag-1A 5’-ATTCAGACGGGGGCGGGAATGTCGGCTTTGAGGGGGCCTGAGTGTCTCTGTCTCTCGTC-3’
Gag-2S 5’-GACGAGAGACAGAGACACTCAGGCCCCCTCAAAGCCGACATTCCCGCCCCCGTCTGAAT-3’
Gag-2A 5’-GAGTGATCTATGGTGGAGACATGGGTGATCCTCATGTGCCGCCTCTTCTTCATTG-3’
HCV- S 5’-CAATGAAGAAGAGGCGGCACATGAGGATCACCCATGTCTCCACCATAGATCACTC-3’
HCV-A 5’-CCTTAATTAAACATGGGTGATCCTCATGTGGTTGGTGTTACGTTTGGTT-3’
Gag-3S 5’-GGACTTTTTGGAGTGGCTTTGTT-3’
Gag-3A 5’-GCGTAAAACCGAAAGCAAAAAT-3’
Gag p FAM5’-ACAGAGACACTTCCCGCCCCCG-3’BHQ
IC p HEX5’-CAGGCCCCCTCAAAGCCGACAT-3’BHQ
b-actin A 5’-CCTGGCACCCAGCACAAT-3’
b-actin S 5’-GCTGATCCACATCTGCTGGAA-3’
b-actin p FAM5’-ATCAAGATCATTGCTCCTCCTGAGCGC-3’TAKARA
FseIa n dPacI restriction enzyme sites are underscored; a C-variant pac site is indicated by boldface type. The broken line indicates the internal control sequences
inserted in the CIC. FAM: 6-carboxyfluorescein; HEX: 6-carboxyhexachlorofluorescein; BHQ: Black hole quencher dye.
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3 copies/μl or IU/
ml, respectively, present in each sample). The standard
curves were generated from serial dilutions of the standards
(10
6 to 10
2 copies/μl or IU/ml, respectively). In addition,
pACYC-MS2-2V or armored RNA standard was used as an
EPC. To control for the integrity of the DNA or RNA, the
cellular b-actin gene was amplified in all clinical specimens
and was tested under the same conditions, but with 0.4 μM
b-actin specific primers and 0.4 μM b-actin specific probe
(5′ FAM, 3′ TAKARA-labelled) (see Table 1).
Results
Construction of XMRV DNA standard and CIC plasmid
The PCR amplification products from the DNA stan-
dard or CIC plasmid (using primer Gag-1S and HCV-A)
were full length (1584 bp and 1606 bp, respectively).
Sequencing demonstrated that the exogenous chimeric
sequences were successfully inserted into the pACYC-
MS2 vector. The PCR products were analyzed by elec-
trophoresis on an agarose gel (1%) (Fig. 2).
Preparation of the viral RNA standard and its internal
control (armored RNAs)
The purified armored RNAs were electrophoresed and a
single band of approximately 1.0 kb could be seen by
agarose gel analysis (Fig. 3). The RT-PCR amplification
products of the RNA extracted from armored RNAs
were analyzed by agarose gel electrophoresis (Fig. 2).
PCR products were then verified by sequencing.
Armored RNAs in EDTA-preserved human plasma
i n c u b a t e da t4 ° C ,3 7 ° C ,a n dr o o mt e m p e r a t u r ew e r e
stable for over 3 months (data not shown).
Figure 1 Construction of CIC by overlapping PCR. During the first-round of PCR, 3 fragments (A, B and C: VP62 33-486 nt, VP62 486-1149,
and the HCV 5’UTR) were amplified from plasmid VP62 (kindly provided by Lombardi) and pNCCL-HCV (constructed by our laboratory) using
primers Gag-1S and Gag-1A, Gag-2S and Gag-2A, and HCV-S and HCV-A. In the first overlapping PCR, fragment D was amplified from fragments
A and B using primers Gag-1S and Gag-2A; the internal probe-binding sequences were introduced into fragment D. Fragment CIC was obtained
by a second overlapping PCR using primers Gag-1S and HCV-A to amplify from fragments D and C.
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armored RNA as a calibrator for XMRV RNA assays, we
used the HCV international standard to calibrate serially
diluted armored RNA. The concentrations of the chi-
m e r i ca r m o r e dR N Af o rt h e5d i l u t i o n s( 1 0
6,1 0
5,1 0
4,
10
3,a n d1 0
2)w e r e5 . 6 3×1 0
6 IU/ml, 6.01 × 10
5 IU/ml,
5.47 × 10
4 IU/ml, 5.36 × 10
3 IU/ml, and 5.75 × 10
2 IU/
ml. The concentrations of the CIC were evaluated in the
same way, at 1.12 × 10
6 IU/ml, 9.78 × 10
4 IU/ml, 1.03 ×
10
4 IU/ml, 1.15 × 10
3 IU/ml, and 1.07 × 10
2 IU/ml.
Multiplex real-time PCR and RT-PCR for XMRV detection
A dilution series of the DNA or RNA XMRV standard
was spiked with 3 different concentrations (10
5 to 10
3
copies/μl or IU/ml) of the CIC and used as a mixed
template. We determined that 1000 copies/μlo fD N A
plasmid or 1000 IU/ml armored RNA was the optimal
CIC concentration for the multiplex real-time assay
(Table 2).
Linear regression analysis of the Ct values against the
log10 XMRV DNA or armored RNA standard concen-
tration yielded r
2 = 0.999. The lowest detectable concen-
tration of XMRV DNA or armored RNA standard was
20 copies/reaction, calculated as 10 copies/μl×2 . 0μl
XMRV DNA standard per reaction, or 10 IU/mL,
respectively (Fig 4).
The specificity of the multiplex real-time assay was
100% in testing of the 45 controls.
Reproducibility was established based on the Ct values
obtained within each run (within-run) and between
runs. The within-run precision CV ranged from 1.76%
to 2.80% or 1.70% to 2.59%, while the between-run CV
ranged from 1.07% to 2.56% or 1.06% to 2.74% (Table 3).
The amounts of XMRV DNA derived from PBMC and
RNA derived from plasma were determined by using the
standard curve method. No signals for the XMRV-speci-
fic probe were detected, while all 65 CFS cases and 65
healthy controls generated positive CIC (1000 copies/μl
or IU/ml, respectively) signals with Ct values between
32 and 36 (Figure 5). The b-actin gene was detected in
all clinical specimens.
Discussion
Sensitive multiplex real-time PCR and RT-PCR assays
with CICs were established to detect XMRV proviral
DNA in PBMCs or viral RNA in plasma, respectively,
from Chinese patients with CFS. The virus was not
detected in any of our study subjects; these results do
not support an association between XMRV and CFS in
Chinese.
Our findings appeared to be inconsistent with a pre-
vious report of XMRV DNA isolation from PBMCs of
CFS patients in the US [3]. Technical differences can be
ruled out as a reason for the failure to detect XMRV.
The sensitivity of the multiplex real-time PCR (20
copies/reaction) was likely to be as sensitive, if not more
Figure 2 Gel electrophoresis of PCR and RT-PCR products. Lane M, DNA marker; Products amplified from pACYC-MS2-2V are represented in
lanes 1-6: lane1, positive control; lane 2, RT-PCR product of RNA extracted from armored RNA; lanes 3-6, the 4 negative controls (H2O, H2O after
extraction and RT, RNA extracted from armored RNAs without RT, and armored RNAs without extraction and RT); lanes 7-12 represent the same
treatments, but amplified from pACYC-MS2-IC-2V.
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thus suggesting that multiplex real-time PCR can be
used for the detection of XMRV proviral DNA. The
end-point PCR method used in the previous study
requires multiple manipulations of the sample after the
amplification step, thus increasing the risk of carryover
contamination. The possibility that proviral DNA degra-
dation during the extraction process may have led to
our negative results seems unlikely. The b-actin gene
was positive for all clinical specimens, confirming the
integrity of the DNA. In addition, samples used in this
research were representative of typical patients with
CFS, which met the 1994 Centers for Disease Control
and Prevention case definition of CFS (called the
Fukuda criteria). Although the patients studied by Lom-
bardi et al [3] were reported to fulfil the same criteria, a
clear description of their patient and control cohorts
was lacking.
Several PCR-based methodologies have been devel-
oped for the detection of XMRV DNA, including end
point and real-time PCR methodologies [4-7]. Beta-glo-
bin gene, GAPDH, and b-actin were used as non-com-
petitive ICs to validate DNA integrity in 4 recent studies
of XMRV [4-7]. However, DNA concentrations may
vary widely between clinical samples. Van Kuppeveld
et al [6] amplified a known amount of phocine distem-
per virus (PDV) that had been added to clinical samples
to monitor RNA quality and to detect amplification
inhibition. Although attractive, the use of live viruses as
internal controls may raise concerns regarding safety
and consistency between preparations. Additionally, the
performance of non-competitive ICs is imperfect due to
Figure 3 Electrophoresis of armored RNAs after purification by gel exclusion chromatography. Lane M, DNA marker; lane 1, armored RNA
standard; lane 2 armored RNA CIC (1% agarose gel ).
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target nucleic acids [15]. Here, we used CIC as a substi-
tute. The CIC was a constructed plasmid which
mimicked the template with the same length and primer
binding sites, and similar GC content. In order to avoid
suppression of target amplification and possible compe-
tition between the target and CIC, we optimized the
concentration of CIC added to the samples. IC concen-
trations of more than 1000 copies/μl altered the Ct of
almost all standards which yielded an underestimation
of the concentration. CIC at 1000 copies/μl was deter-
mined to be optimal for our real-time assay. Our results
indicated that no inhibitory effects were at play in the
multiplex real-time assay we used to screen our study
population.
The pathogenesis and outcome of XMRV infection
may be associated or even causally linked with plasma
viral RNA loads, as well as proviral loads. In addition to
XMRV proviral DNA detection, we developed a sensi-
tive multiplex real-time RT-PCR assay to detect XMRV
Table 2 Optimization of CIC concentration
(1) Multiplex real-time PCR
pACYC-MS2- IC-2V plasmid CIC
concentration (copies/μl)
pACYC-MS2-2V
plasmid standard 1
×1 0
5 copies/μl
pACYC-MS2-2V
plasmid standard 1
×1 0
4 copies/μl
pACYC-MS2-2V
plasmid standard 1
×1 0
3 copies/μl
pACYC-MS2-2V
plasmid standard 1
×1 0
2 copies/μl
XMRV 0
copies/μl
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
((FAM)Ct
CIC (HEX)Ct
100000 39.22 28.79 32.18 31.58 28.92 34.81 28.50 No Ct 28.34
10000 37.85 28.12 31.26 31.06 32.36 34.56 31.45 44.26 31.55
1000 39.52 24.73 37.20 27.76 31.50 31.18 35.79 34.28 34.11
0 No Ct 24.69 No Ct 28.47 No Ct 30.73 No Ct 33.81 No Ct
(2) Multiplex real-time RT-PCR
Armored RNA concentration (IU/ml) Armored RNA
standard 1 × 10
5
IU/ml
Armored RNA
standard 1 × 10
4
IU/ml
Armored RNA
standard 1 × 10
3
IU/ml
Armored RNA
standard 1 × 10
2
IU/ml
XMRV 0 IU/
ml
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC
(HEX)Ct
XMRV
(FAM)Ct
CIC (HEX)Ct
100000 39.50 25.24 30.89 28.28 27.12 No Ct 26.35 No Ct 26.07
10000 37.96 25.00 30.70 28.22 30.37 31.17 27.79 37.06 29.49
1000 No Ct 25.25 30. 65 28.03 33.18 31.14 33.87 34.40 33.27
0 No Ct 25.18 No Ct 27. 82 No Ct 30.78 No Ct 37.11 No Ct
Ct values indicate the standard concentrations. A sample with Ct > 45 cycles was considered to be negative. Concentrations of XMRV DNA/RNA and pACYC-MS2-
2V plasmid/armored RNA standard were indicated by FAM and HEX signals, respectively.
Figure 4 Linearity and sensitivity of the DNA or armored RNA standards in the multiplex real-time assay. Standard curves of the DNA
standard (A) and RNA standard (B) were linear. Amplification of ten-fold serial dilutions from 10
6 copies/μl to 10 copies/μlo r1 0
6 IU/ml to 10
IU/ml of the standard demonstrated a standard curve R
2 of 0.999, which was yielded by plotting the Ct values against the log10 XMRV DNA or
RNA standard concentration.
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serve as the XMRV viral RNA standard and CIC to eval-
uate the analytical linearity, sensitivity, specificity, and
reproducibility of the detection assay. Both were stable
in normal human EDTA-preserved plasma at 4°C, 37°C,
a n dr o o mt e m p e r a t u r ef o ro v e r3m o n t h s .A r m o r e d
RNA is a kind of non-infectious recombinant virus-like
particle (VLP) containing target exogenous RNA. In
comparison to naked RNA, as armored RNA is a more
suitable candidate for a positive control or standard in
the quantification of RNA viruses, because it is RNase-
resistant, stable, non-infectious, and easily extracted by
conventional methods [16-19]. Moreover, armored RNA
can serve as a control for all stages of the RT-PCR
assay, from extraction through amplification. The inclu-
sion of the HCV 5′UTR made it easy to assign an IU
value to the XMRV RNA and the CIC within the
armored RNA, avoiding the necessity for the complex
procedures involved in value assignment of calibrators
or standards when international standards (IS) are not
available [12]. These characteristics of armored RNA
ensure the validity of our data. Conflicting results have
made the associations between XMRV and CFS unclear;
it is therefore important to produce a ‘universal’ XMRV
standard so that the results of different assays may be
compared. By using an armored RNA standard, different
research groups and clinical laboratories may directly
compare their quantitative data. Nevertheless, we did
not detect XMRV viral RNA with our armored RNA-
standardised method in plasma samples from a Chinese
study population.
These findings may not be generalisable beyond the
study population because XMRV infection rates may
vary geographically. Similarly, although XMRV was initi-
ally discovered in tumour tissues of a subset of patients
with prostate cancer [20], other studies have shown a
variable incidence of the virus in prostate tumours. One
US study found XMRV in up to 23% of prostate cancer
tumours [21]; however, a recent German study found a
0% incidence of XMRV [22]. Additional research is
needed to determine what, if any, role XMRV plays in
CFS in Chinese patients.
Conclusions
This study failed to show the presence of XMRV in
PBMCs and plasma of Chinese patients with CFS using
the multiplex real-time PCR assay; these results do not
support an association between XMRV and CFS in peo-
ple of Chinese ancestry.
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Table 3 Reproducibility of the real-time PCR/RT-PCR assay
Reproducibility XMRV DNA/RNA (copies/μl/IU/ml) Number of determinations Mean Ct (DNA/RNA) SD (DNA/RNA) CV(%) (DNA/RNA)
within-run 10
5 10 24.47/25.13 0.50/0.52 2.03/2.06
10
4 10 27.25/27.99 0.48/0.48 1.76/1.70
10
2 10 33.81/34.62 0.94/0.90 2.80/2.59
between-run 10
5 10 24.97/26.17 0.28/0.32 1.14/1.23
10
4 10 27.98/29.14 0.30/0.31 1.07/1.06
10
2 10 34.43/35.94 0.88/0.99 2.56/2.74
Figure 5 Multiplex real-time assay for detection of patient XMRV proviral DNA or viral RNA Examples of viral RNA screen of 25 CFS
patient plasma samples including CICs in each reaction. (A) Amplification plot for a plasma sample obtained from a CFS patient: No XMRV-
specific signals were detected. S1-S5 were armored RNA standards (from 10
7 to 10
3 IU/ml), pc was an armored RNA EPC. (B) Amplification plot of
the CICs (1000 IU/ml), which were added to patient samples.
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